EGFR and lung cancer: The combination of withaferin A and other anticancer drugs, such as cisplatin and pemetrexed, showed synergistic results in the inhibition of the epidermal growth factor receptor (EGFR) and wild-type lung cancer cell viability, and further increased the cytotoxic effect of cisplatin [158].